Skip to main content
Journal cover image

Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo.

Publication ,  Journal Article
DiMaio, JM; Clary, BM; Via, DF; Coveney, E; Pappas, TN; Lyerly, HK
Published in: Surgery
August 1994

BACKGROUND: Directed enzyme pro-drug therapy incorporates the delivery of a gene to a cancer cell that will be specifically expressed and will confer sensitivity to a therapeutic agent. Tumor-specific gene expression can be achieved by coupling the promoter for the carcinoembryonic antigen (CEA) to a gene such as herpes simplex virus thymidine kinase (HSV-tk), which phosphorylates ganciclovir to a potent DNA synthesis inhibitor. METHODS: Retroviral vectors were constructed to contain the CEA promoter coupled to HSV-tk (LN-CEA-TK) and were used to transduce the CEA-expressing pancreatic carcinoma cell line BXPC3. Recombinant pancreatic carcinoma cell lines expressing HSV-tk (BXPC3CEA-TK) were then tested for sensitivity to the toxic effects on ganciclovir after engraftment into severe combined immunodeficient mice. Tumors were generated by subcutaneous inoculation of 20 x 10(6) tumor cells consisting of BXPC3 and/or BXPC3CEA-TK cells in ratios of 100:0, 90:10, 50:50, 10:90, and 0:100. After 3 days mice received daily ganciclovir (0.1 mg/kg) or phosphate-buffered saline solution by intraperitoneal injection and were monitored for tumor growth. RESULTS: All severe combined immunodeficient mice inoculated with BXPC3 or BXPC3CEA-TK cells in any proportion developed large pancreatic tumors. As expected, a significant reduction in tumor size was seen in the BXPC3CEA-TK engrafted mice receiving ganciclovir compared with mice receiving phosphate-buffered saline solution or mice engrafted with only BXPC3. In addition, all animals with any fraction of cells expressing HSV-tk exhibited a significant reduction in tumor growth, including animals with only 10% of cells expressing HSV-tk. CONCLUSIONS: These results suggest the potential utility of directed enzyme pro-drug therapy in patients with CEA-expressing pancreatic carcinoma.

Duke Scholars

Published In

Surgery

ISSN

0039-6060

Publication Date

August 1994

Volume

116

Issue

2

Start / End Page

205 / 213

Location

United States

Related Subject Headings

  • Thymidine Kinase
  • Surgery
  • Simplexvirus
  • Retroviridae
  • Prodrugs
  • Pancreatic Neoplasms
  • Molecular Sequence Data
  • Mice, SCID
  • Mice
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
DiMaio, J. M., Clary, B. M., Via, D. F., Coveney, E., Pappas, T. N., & Lyerly, H. K. (1994). Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery, 116(2), 205–213.
DiMaio, J. M., B. M. Clary, D. F. Via, E. Coveney, T. N. Pappas, and H. K. Lyerly. “Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo.Surgery 116, no. 2 (August 1994): 205–13.
DiMaio JM, Clary BM, Via DF, Coveney E, Pappas TN, Lyerly HK. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery. 1994 Aug;116(2):205–13.
DiMaio, J. M., et al. “Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo.Surgery, vol. 116, no. 2, Aug. 1994, pp. 205–13.
DiMaio JM, Clary BM, Via DF, Coveney E, Pappas TN, Lyerly HK. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery. 1994 Aug;116(2):205–213.
Journal cover image

Published In

Surgery

ISSN

0039-6060

Publication Date

August 1994

Volume

116

Issue

2

Start / End Page

205 / 213

Location

United States

Related Subject Headings

  • Thymidine Kinase
  • Surgery
  • Simplexvirus
  • Retroviridae
  • Prodrugs
  • Pancreatic Neoplasms
  • Molecular Sequence Data
  • Mice, SCID
  • Mice
  • Humans